What is acute myeloid leukemia? Acute myeloid leukemia (AML) is a malignant disease of myeloid hematopoietic stem/progenitor cells. It is characterized by abnormal proliferation of primitive and naive myeloid cells in the bone marrow and peripheral blood, with an incidence of 2.3/100,000, slightly more in men than in women, and an increasing incidence with age. Clinical manifestations of acute myeloid leukemia: Clinical manifestations include anemia, bleeding, infection and fever, organ infiltration, metabolic abnormalities, etc. Most cases are acute and severe, and the prognosis is dangerous, often life-threatening if not treated in time. Classification and risk level of acute myeloid leukemia: Acute myeloid leukemia can be clinically classified into M0 to M7, with a total of 8 types. M1 acute myeloid leukemia immature type M2 acute myeloid leukemia partially mature type M3 acute promyelocytic leukemia M4 acute granulocytic leukemia M5 acute monocytic leukemia M6 acute erythroblastic leukemia M7 acute megakaryocytic leukemia M0 acute minimally differentiated granulocytic leukemia How should acute myeloid leukemia be treated? Treatment is essentially the same in all subtypes of AML, except APL. Induction remission chemotherapy; post-remission treatment including high-dose intensive therapy and maintenance therapy; hematopoietic stem cell transplantation remains an important option for curing AML. Targeted therapy, demethylation therapy and cellular immunotherapy have also shown promising therapeutic effects and have become new research directions for AML treatment.